BioSpace News Archive

Immunomedics, Inc. , (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Trodelvy (sacituzumab govitecan-hziy) is now available through major specialty distributors in the United States and that the first patient was treated with commercial product on April 29, 2020. Trodelvy is the first anti-Trop-2 ADC recently approved by the U.S.

The Osteoarthritis Action Alliance, in partnership with the Centers for Disease Control and Prevention and the Arthritis Foundation, have updated the National Public Health Agenda for Osteoarthritis for 2020.

Phase 1/2 Clinical Trial for ALM-488 to Highlight Nerves in Patients Undergoing Head & Neck Surgery Will Begin Enrollment at the University California San Diego (UCSD), Stanford and Harvard [04-May-2020] LA JOLLA, Calif. , May 4, 2020 /PRNewswire/ -- Alume Biosciences, Inc. , a biotechnology company developing nerve-targeted pharmaceuticals for surgical and the

Sesen Bio to Host Conference Call to Review First Quarter Financial Results and to Provide Operational Update Highlighting Positive Progress Towards Demonstrating Analytical Comparability CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on M

KIYATEC, Inc. today announced the appointment of Bruce Nash, MD, MBA, to its Board of Directors. Dr. Nash brings over 30 years of executive-level healthcare experience in the managed care, hospital and medical group practice settings. Currently, he serves as Chief Physician Executive and Senior Vice President at Blue Cross Blue Shield of Massachusetts, one of the nation’s leading health insurance plans. During his caree

Teva and Celltrion Healthcare Announce the Launch of TRUXIMA ® (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan ® (rituximab) Available in the United States for This Indication TRUXIMA is also now available for the treatment of Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)

Company provides updates on recent regulatory, clinical, operational, and business developments

Sharps Compliance Corp., a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, announced the appointment of Jack Holmes to its Board of Directors.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the Company will release financial results for the first quarter ended March 31, 2020 on Wednesday, May 13, 2020, before the market opens. Following the release, Dr. Frank Bedu-Addo, Chief Executiv

La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2020. For the three months ended March 31, 2020, GIAPREZA U.S. net sales were $7.6 million, up 73% from the three months ended March 31, 2019 and up 5% from the three mo